UPDATE: Ratiopharm to be sold after Merckle suicide

12 January 2009

German billionaire entrepeneur Adolf Merckle, whose generics firm Ratiopharm is to be sold to cover mounting debts, has taken his own  life, his family has said.

In a statement, Mr Merckle's wife and children said that helplessness in  the face of the financial crisis had "broken" the industrialist. He was  hit by a train near his home in Blaubeurne on the evening of January 5.

Mr Merckle's drug empire, which also includes Germany's biggest drug  wholesaler Phoenix Pharmahandel, is to be offered as collateral on a  loan extension from 40 banks that he was unable to repay on time at the  end of last year as his VEM empire had amassed a reported 5.0 billion  euros in debts ($6.81 billion). The entrepeneur lost out heavily by  short-selling stock in car-maker Volkswagen, along with a series of  highly-leveraged acquisitions in recent years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight